Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Forst

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
Expert Opinion on Pharmacotherapy|June 25, 2016
Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitusThomas Forst
Lancet (London, England)|July 9, 2010
Dapagliflozin, an SGLT2 inhibitor, for diabetesMarkolf Hanefeld, Thomas Forst
Journal of Diabetes Science and Technology|July 5, 2011
Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazoneAndreas Pfützner, Thomas Forst
Experimental Diabetes Research|September 24, 2008
New tricks by an old dogThomas Forst, John Wahren
Expert Opinion on Pharmacotherapy|December 14, 2011
Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetesThomas Forst, Andreas Pfützner
Klinische Monatsblatter Fur Augenheilkunde|November 17, 2020
Diabetic Macular Edema in Diabetological PracticesGeorg Michelson, Thomas Forst
Expert Review of Endocrinology & Metabolism|February 13, 2019
Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitusThomas Forst, Andreas Pfützner
Expert Opinion on Drug Delivery|November 22, 2005
Pulmonary insulin delivery by means of the Technosphere drug carrier mechanismAndreas Pfützner, Thomas Forst
Expert Opinion on Pharmacotherapy|March 1, 2006
Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortalityAndreas Pfützner, Thomas Forst
Expert Opinion on Pharmacotherapy|October 4, 2013
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitusThomas Forst, Andreas Pfützner
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
Expert Opinion on Pharmacotherapy|June 25, 2016
Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitusThomas Forst
Lancet (London, England)|July 9, 2010
Dapagliflozin, an SGLT2 inhibitor, for diabetesMarkolf Hanefeld, Thomas Forst
Journal of Diabetes Science and Technology|July 5, 2011
Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazoneAndreas Pfützner, Thomas Forst
Experimental Diabetes Research|September 24, 2008
New tricks by an old dogThomas Forst, John Wahren
Expert Opinion on Pharmacotherapy|December 14, 2011
Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetesThomas Forst, Andreas Pfützner
Klinische Monatsblatter Fur Augenheilkunde|November 17, 2020
Diabetic Macular Edema in Diabetological PracticesGeorg Michelson, Thomas Forst
Expert Review of Endocrinology & Metabolism|February 13, 2019
Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitusThomas Forst, Andreas Pfützner
Expert Opinion on Drug Delivery|November 22, 2005
Pulmonary insulin delivery by means of the Technosphere drug carrier mechanismAndreas Pfützner, Thomas Forst
Expert Opinion on Pharmacotherapy|March 1, 2006
Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortalityAndreas Pfützner, Thomas Forst
Expert Opinion on Pharmacotherapy|October 4, 2013
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitusThomas Forst, Andreas Pfützner
Pageof 15